Targeting apoptosis in cancer therapy

MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells

(2019) Qing Wang et al.   LEUKEMIA & LYMPHOMA

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

(2019) Rumani Singh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

(2019) Warren Fiskus et al.   Blood Cancer Journal

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1

(2019) Thomas J. Ow et al.   Oncotarget

Mitochondrial origins of fractional control in regulated cell death

(2019) Luís C. Santos et al.   Nature Communications

Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma

(2019) Jong-Sung Park et al.   Nature Communications

ER stress sensor, glucose regulatory protein 78 (GRP78) regulates redox status in pancreatic cancer thereby maintaining “stemness”

(2019) Patricia Dauer et al.   Cell Death & Disease

Small-molecule allosteric inhibitors of BAX

(2019) Thomas P. Garner et al.   Nature Chemical Biology

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

(2019) Claudia Iavarone et al.   MOLECULAR CANCER THERAPEUTICS

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

(2019) Andrew H. Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of MCL1 function sensitizes the MDA‐MB‐231 breast cancer cells to rh‐TRAIL by increasing DR4 levels

(2019) Anna Blasio et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma

(2019) Vijay G. Ramakrishnan et al.   HAEMATOLOGICA

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

(2019) Andrew D. Zelenetz et al.   BLOOD

2OA phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors

(2019) A W Tolcher et al.   ANNALS OF ONCOLOGY

Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues

(2019) Paul R. Graves et al.   ACS Chemical Biology

Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex

(2019) Guohai Zhang et al.   BIOCHEMICAL PHARMACOLOGY

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

(2019) Andrew W. Roberts et al.   BLOOD

Targeting Ferroptosis to Iron Out Cancer

(2019) Behrouz Hassannia et al.   CANCER CELL

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality

(2019) Jo Ishizawa et al.   CANCER CELL

The Coming Decade of Cell Death Research: Five Riddles

(2019) Douglas R. Green   CELL

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

(2019) Dana Prukova et al.   CLINICAL CANCER RESEARCH

The kinase PERK and the transcription factor ATF4 play distinct and essential roles in autophagy resulting from tunicamycin-induced ER stress

(2019) Morten Luhr et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.

(2019) Isabel Arrillaga et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

(2019) Marwan Fakih et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.

(2019) Mark J. Ratain et al.   JOURNAL OF CLINICAL ONCOLOGY

A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.

(2019) Rosalyn A. Juergens et al.   JOURNAL OF CLINICAL ONCOLOGY

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report

(2019) Matthew D. Hall et al.   Journal of Neurosurgery-Pediatrics

LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma

(2019) Linlin Yang et al.   MOLECULAR CANCER THERAPEUTICS

Salinomycin-Loaded Gold Nanoparticles for Treating Cancer Stem Cells by Ferroptosis-Induced Cell Death

(2019) Yongmei Zhao et al.   MOLECULAR PHARMACEUTICS

Ibrutinib and Venetoclax for First-Line Treatment of CLL

(2019) Nitin Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation

(2019) Corey Rogers et al.   Nature Communications

Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment

(2019) Xufeng Chen et al.   Cancer Discovery

The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells

(2019) Tamilla Nechiporuk et al.   Cancer Discovery

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

(2019) Mark N. Stein et al.   Journal for ImmunoTherapy of Cancer

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma

(2019) Piers Blombery et al.   BRITISH JOURNAL OF HAEMATOLOGY

Autophagy-Independent Functions of the Autophagy Machinery

(2019) Lorenzo Galluzzi et al.   CELL

Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification

(2019) J. Cornillie et al.   Clinical & Translational Oncology

ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression

(2019) Feven Tameire et al.   NATURE CELL BIOLOGY

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

(2019) Kirsten Fischer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The interaction between SPARC and GRP78 interferes with ER stress signaling and potentiates apoptosis via PERK/eIF2α and IRE1α/XBP-1 in colorectal cancer

(2019) Yi-Jye Chern et al.   Cell Death & Disease

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

(2019) Richard W. Birkinshaw et al.   Nature Communications

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists

(2019) Justyna Kocik et al.   Cancers

Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity

(2019) Annelise G. Snyder et al.   Science Immunology

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

(2019) Smit Kour et al.   MOLECULAR PHARMACOLOGY

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

(2018) Jennifer Tsoi et al.   CANCER CELL

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

(2018) Steven Blotner et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

BCL-x L -selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis

(2018) Sara Fatima Faqar-Uz-Zaman et al.   CANCER LETTERS

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib

(2018) Jupeng Yuan et al.   Clinical Lung Cancer

Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2

(2018) Tomoko Takimoto-Shimomura et al.   INVESTIGATIONAL NEW DRUGS

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

(2018) Jessica Wagner et al.   JOURNAL OF CLINICAL INVESTIGATION

Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma

(2018) Behrouz Hassannia et al.   JOURNAL OF CLINICAL INVESTIGATION

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

(2018) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

New therapeutic strategies to treat human cancers expressing mutant p53 proteins

(2018) Giovanni Blandino et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells

(2018) Zhaodong Li et al.   LEUKEMIA

Kinase-targeted cancer therapies: progress, challenges and future directions

(2018) Khushwant S. Bhullar et al.   Molecular Cancer

Ferroptosis-Induced Endoplasmic Reticulum Stress: Cross-talk between Ferroptosis and Apoptosis

(2018) Young-Sun Lee et al.   MOLECULAR CANCER RESEARCH

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

(2018) Constantine S. Tam et al.   NEW ENGLAND JOURNAL OF MEDICINE

BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis

(2018) Ulrike Heinicke et al.   ONCOGENE

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

(2018) Anthony Tolcher et al.   ONCOLOGIST

Iterative optimization yields Mcl-1–targeting stapled peptides with selective cytotoxicity to Mcl-1–dependent cancer cells

(2018) Raheleh Rezaei Araghi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis

(2018) Kate McArthur et al.   SCIENCE

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

(2018) Luis A. Carvajal et al.   Science Translational Medicine

Crystal Structures of Anti-apoptotic BFL-1 and Its Complex with a Covalent Stapled Peptide Inhibitor

(2018) Edward P. Harvey et al.   STRUCTURE

Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells

(2018) Federico Lucantoni et al.   Cell Death & Disease

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc

(2018) Ning Li et al.   Cell Death & Disease

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

(2018) Qiang Zhang et al.   Cell Death & Disease

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

(2018) Samuel Y. Ng et al.   Nature Communications

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

(2018) Carmen D. Herling et al.   Nature Communications

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

(2018) Patrick Casara et al.   Oncotarget

BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose

(2018) Federico Lucantoni et al.   Oncotarget

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma

(2018) Changhoon Yoo et al.   Cancer Research and Treatment

p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells

(2018) Amy Tarangelo et al.   Cell Reports

Role of Dopamine Receptors in the Anticancer Activity of ONC201

(2018) Christina Leah B. Kline et al.   NEOPLASIA

The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy

(2018) Guochao Liao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial

(2018) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

(2018) Nehal J. Lakhani et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

(2018) Donia M. Moujalled et al.   LEUKEMIA

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma

(2018) Shalin Shah et al.   MELANOMA RESEARCH

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity

(2018) Ryan S. Soderquist et al.   Nature Communications

A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia

(2018) Haley E. Ramsey et al.   Cancer Discovery

Exploiting MCL-1 dependency with combination MEK + MCL-1 inhibitors leads to induction of apoptosis and tumor regression in KRAS mutant non-small cell lung cancer

(2018) Varuna Nangia et al.   Cancer Discovery

Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer

(2018) Rachel M. Guerra et al.   Cell Reports

MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells

(2018) Lin Lin et al.   Oncogenesis

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma

(2018) Yvonne de Jong et al.   Oncogenesis

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

(2018) Varun Vijay Prabhu et al.   CLINICAL CANCER RESEARCH

SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer

(2018) Zhen Tao et al.   CLINICAL CANCER RESEARCH

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma

(2018) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

(2018) Rishu Agarwal et al.   NATURE MEDICINE

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death

(2018) Yuxuan Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection

(2018) Joseph Sarhan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pathogen blockade of TAK1 triggers caspase-8–dependent cleavage of gasdermin D and cell death

(2018) Pontus Orning et al.   SCIENCE

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

(2018) Adriana E. Tron et al.   Nature Communications

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia

(2018) Piers Blombery et al.   Cancer Discovery

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

(2018) Lukasz Skalniak et al.   Cancers

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

(2017) Maja de Jonge et al.   EUROPEAN JOURNAL OF CANCER

A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY

(2017) S. Le Gouill et al.   HEMATOLOGICAL ONCOLOGY

Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

(2017) Angelo Aguilar et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pathways and mechanisms of venetoclax resistance

(2017) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells

(2017) Marisa A. Fuse et al.   MOLECULAR CANCER THERAPEUTICS

The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2

(2017) Torsten Hartwig et al.   MOLECULAR CELL

GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance

(2017) Christine Baumann et al.   Molecular Oncology

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

(2017) Matthew J. Hangauer et al.   NATURE

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

(2017) Vasanthi S. Viswanathan et al.   NATURE

Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency

(2017) Evangelos Giampazolias et al.   NATURE CELL BIOLOGY

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

(2017) Joel D. Leverson et al.   Cancer Discovery

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

(2017) Viktor Arnhold et al.   Oncotarget

MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas

(2017) Audrey Laroche et al.   Oncotarget

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

(2017) Shaomeng Wang et al.   Cold Spring Harbor Perspectives in Medicine

Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells

(2017) Shihui Hao et al.   NEOPLASIA

Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.

(2017) B. I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

(2016) T. Ciuleanu et al.   ANNALS OF ONCOLOGY

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

(2016) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

(2016) D. Chiron et al.   BLOOD

Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo

(2016) Z. Tao et al.   CLINICAL CANCER RESEARCH

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

(2016) A. W. Tolcher et al.   CLINICAL CANCER RESEARCH

Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors

(2016) Taekyu Lee et al.   FEBS LETTERS

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

(2016) B. Reis et al.   HAEMATOLOGICA

The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death

(2016) Roslyn N. Crowder et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis

(2016) Kenichi Shimada et al.   Nature Chemical Biology

IAP antagonists induce anti-tumor immunity in multiple myeloma

(2016) Marta Chesi et al.   NATURE MEDICINE

Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth

(2016) Sung Eun Kim et al.   Nature Nanotechnology

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases

(2016) C. Leah B. Kline et al.   Science Signaling

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

(2016) Jo Ishizawa et al.   Science Signaling

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

(2016) Joonil Jung et al.   Nature Communications

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

(2016) Mohammed Najim Abed et al.   Journal of Ovarian Research

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

(2016) Rob N. de Jong et al.   PLOS BIOLOGY

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

(2016) B. Reis et al.   HAEMATOLOGICA

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases

(2016) C. Leah B. Kline et al.   Science Signaling

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

(2016) Jo Ishizawa et al.   Science Signaling

CLPB Mutations Cause 3-Methylglutaconic Aciduria, Progressive Brain Atrophy, Intellectual Disability, Congenital Neutropenia, Cataracts, Movement Disorder

(2015) Saskia B. Wortmann et al.   AMERICAN JOURNAL OF HUMAN GENETICS

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†

(2015) G. R. Blumenschein et al.   ANNALS OF ONCOLOGY

Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma

(2015) H. G. Smith et al.   ANNALS OF SURGICAL ONCOLOGY

Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax

(2015) Aisha Shamas-Din et al.   BIOCHEMICAL JOURNAL

Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma

(2015) Lu Dai et al.   BLOOD

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer

(2015) Anne M. Noonan et al.   CANCER

Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis

(2015) Silvia von Karstedt et al.   CANCER CELL

The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells

(2015) Christophe Louandre et al.   CANCER LETTERS

Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner

(2015) V. V. Prabhu et al.   CANCER RESEARCH

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

(2015) M. Andreeff et al.   CLINICAL CANCER RESEARCH

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

(2015) A. Forero-Torres et al.   CLINICAL CANCER RESEARCH

Promises and Challenges of Smac Mimetics as Cancer Therapeutics

(2015) S. Fulda   CLINICAL CANCER RESEARCH

Peptide therapeutics: Targeting the undruggable space

(2015) Natia Tsomaia   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

(2015) Thomas J. Kipps et al.   LEUKEMIA & LYMPHOMA

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

(2015) R. K. Amaravadi et al.   MOLECULAR CANCER THERAPEUTICS

Mitochondrial Shape Governs BAX-Induced Membrane Permeabilization and Apoptosis

(2015) Thibaud T. Renault et al.   MOLECULAR CELL

Ferroptosis as a p53-mediated activity during tumour suppression

(2015) Le Jiang et al.   NATURE

Metabolic pathways promoting cancer cell survival and growth

(2015) Lindsey K. Boroughs et al.   NATURE CELL BIOLOGY

mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation

(2015) K He et al.   ONCOGENE

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

(2015) David Hong et al.   Science Translational Medicine

Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds

(2015) A.R.M. Ruhul Amin et al.   SEMINARS IN CANCER BIOLOGY

Cell Death Signaling

(2015) Douglas R. Green et al.   Cold Spring Harbor Perspectives in Biology

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin

(2015) Zuzanna Baranski et al.   Oncotarget

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

(2015) Chan Yoon Cheah et al.   Lancet Haematology

Regulated Cell Death: Signaling and Mechanisms

(2014) Avi Ashkenazi et al.   Annual Review of Cell and Developmental Biology

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

(2014) V. Fresquet et al.   BLOOD

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

(2014) Jonathan D. Graves et al.   CANCER CELL

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

(2014) A. N. Hata et al.   CANCER RESEARCH

Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production

(2014) Michael J. White et al.   CELL

Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA

(2014) Anthony Rongvaux et al.   CELL

Regulation of Ferroptotic Cancer Cell Death by GPX4

(2014) Wan Seok Yang et al.   CELL

First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

(2014) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer

(2014) G. L. Johnson et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   Clinical Lung Cancer

Die another way – non-apoptotic mechanisms of cell death

(2014) Stephen W. G. Tait et al.   JOURNAL OF CELL SCIENCE

Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors

(2014) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress

(2014) Loren D. Walensky et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

(2014) James M. Bogenberger et al.   LEUKEMIA & LYMPHOMA

Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK+ anaplastic large cell lymphoma

(2014) Farid Saei Hamedani et al.   LEUKEMIA RESEARCH

Mst1 Promotes Cardiac Myocyte Apoptosis through Phosphorylation and Inhibition of Bcl-xL

(2014) Dominic P. Del Re et al.   MOLECULAR CELL

Structural Model of Active Bax at the Membrane

(2014) Stephanie Bleicken et al.   MOLECULAR CELL

Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts

(2014) Fariba Némati et al.   PLoS One

Regulation of NF-κB by TNF family cytokines

(2014) Matthew S. Hayden et al.   SEMINARS IN IMMUNOLOGY

The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells

(2014) Lijun Ye et al.   TUMOR BIOLOGY

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer

(2014) Y Loriot et al.   Cell Death & Disease

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL

(2014) Michael F. T. Koehler et al.   ACS Medicinal Chemistry Letters

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

Small-molecule Bax agonists for cancer therapy

(2014) Meiguo Xin et al.   Nature Communications

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199

(2014) T. N. Chonghaile et al.   Cancer Discovery

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling

(2014) M. Will et al.   Cancer Discovery

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

(2013) S. Beurlet et al.   BLOOD

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer

(2013) Charles S. Fuchs et al.   CANCER

Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer

(2013) D. Park et al.   CANCER RESEARCH

Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1

(2013) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

(2013) Zev A. Wainberg et al.   Clinical Colorectal Cancer

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

(2013) Sunil Sharma et al.   INVESTIGATIONAL NEW DRUGS

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Luis Paz-Ares et al.   Journal of Thoracic Oncology

BH3 profiling in whole cells by fluorimeter or FACS

(2013) Jeremy Ryan et al.   METHODS

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

(2013) F. Abulwerdi et al.   MOLECULAR CANCER THERAPEUTICS

BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response

(2013) Kristopher A. Sarosiek et al.   MOLECULAR CELL

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

(2013) Yong S. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

(2013) J. E. Allen et al.   Science Translational Medicine

Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation

(2013) J. Silke et al.   Cold Spring Harbor Perspectives in Biology

Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I’ mode

(2013) B Gillissen et al.   Cell Death & Disease

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells

(2012) Twee Tsao et al.   ANNALS OF HEMATOLOGY

Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90

(2012) Joerg Bussenius et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

(2012) Ryan B. Corcoran et al.   CANCER CELL

BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions

(2012) Victoria Del Gaizo Moore et al.   CANCER LETTERS

CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies

(2012) Shuang Chen et al.   CANCER RESEARCH

Interleukin-6 signaling pathway in targeted therapy for cancer

(2012) Yuqi Guo et al.   CANCER TREATMENT REVIEWS

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

(2012) Tongyuan Li et al.   CELL

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

(2012) Thanh-Trang Vo et al.   CELL

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors

(2012) M. M. Centenera et al.   CLINICAL CANCER RESEARCH

Targeting the Bcl-2 family for cancer therapy

(2012) Shibu Thomas et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors

(2012) Melinda S. Merchant et al.   JOURNAL OF CLINICAL ONCOLOGY

Direct and selective small-molecule activation of proapoptotic BAX

(2012) Evripidis Gavathiotis et al.   Nature Chemical Biology

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

Targeting IAP proteins for therapeutic intervention in cancer

(2012) Simone Fulda et al.   NATURE REVIEWS DRUG DISCOVERY

Inhibition of oncogenic Wnt signaling through direct targeting of  -catenin

(2012) T. N. Grossmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterization of Peptide Aptamers Targeting Bfl-1 Anti-Apoptotic Protein

(2011) G. Brien et al.   BIOCHEMISTRY

Combined modality therapy with TRAIL or agonistic death receptor antibodies

(2011) Hope M. Amm et al.   CANCER BIOLOGY & THERAPY

Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol

(2011) Frank Edlich et al.   CELL

Measuring and Modeling Apoptosis in Single Cells

(2011) Sabrina L. Spencer et al.   CELL

Programmed Cell Death in Animal Development and Disease

(2011) Yaron Fuchs et al.   CELL

BCL2A1: the underdog in the BCL2 family

(2011) M Vogler   CELL DEATH AND DIFFERENTIATION

Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial Dynamics

(2011) Jean-Claude Martinou et al.   DEVELOPMENTAL CELL

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results of Tumor Necrosis Factor α– and Melphalan-Based Isolated Limb Perfusion in Locally Advanced Extremity Soft Tissue Sarcomas

(2011) Jan P. Deroose et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure of the Stapled p53 Peptide Bound to Mdm2

(2011) Sohee Baek et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

(2011) Hiroyuki Inuzuka et al.   NATURE

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

(2011) M H Aziz et al.   ONCOGENE

Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients

(2011) Engin Ulukaya et al.   Radiology and Oncology

BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors

(2011) A. C. Faber et al.   Cancer Discovery

Proteasome inhibitors in cancer therapy

(2011) Lisa J. Crawford et al.   Journal of Cell Communication and Signaling

Current strategies to target p53 in cancer

(2010) Fang Chen et al.   BIOCHEMICAL PHARMACOLOGY

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

(2010) A Younes et al.   BRITISH JOURNAL OF CANCER

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

(2010) Margaret A. Park et al.   CANCER BIOLOGY & THERAPY

Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts

(2010) K. Michaud et al.   CANCER RESEARCH

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

(2010) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma

(2010) Bernhard Gillissen et al.   JOURNAL OF CELL BIOLOGY

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

The Proapoptotic Function of Noxa in Human Leukemia Cells Is Regulated by the Kinase Cdk5 and by Glucose

(2010) Xazmin H. Lowman et al.   MOLECULAR CELL

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

(2010) Michelle L Stewart et al.   Nature Chemical Biology

Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim

(2010) Jieru Meng et al.   PLoS One

Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes

(2010) J. A. Ryan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

(2009) H. A. Wakelee et al.   ANNALS OF ONCOLOGY

Cell Death: A New Par-4 the TRAIL

(2009) Lori S. Hart et al.   CELL

The Tumor Suppressor Par-4 Activates an Extrinsic Pathway for Apoptosis

(2009) Ravshan Burikhanov et al.   CELL

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

(2009) Piyush B. Gupta et al.   CELL

Targeting the Apoptosome for Cancer Therapy

(2009) E. C. Ledgerwood et al.   CLINICAL CANCER RESEARCH

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

(2009) C. H. Mom et al.   CLINICAL CANCER RESEARCH

Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Gliomas

(2009) A. Elias et al.   CLINICAL CANCER RESEARCH

Life and death by death receptors

(2009) Maria Eugenia Guicciardi et al.   FASEB JOURNAL

Following TRAIL’s path in the immune system

(2009) Christina Falschlehner et al.   IMMUNOLOGY

Caspase-independent Mitochondrial Cell Death Results from Loss of Respiration, Not Cytotoxic Protein Release

(2009) Lydia Lartigue et al.   MOLECULAR BIOLOGY OF THE CELL

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib

(2009) T. A. Luster et al.   MOLECULAR CANCER THERAPEUTICS

Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis

(2009) Hyungjin Kim et al.   MOLECULAR CELL

Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis

(2009) Sabrina L. Spencer et al.   NATURE

Bid: a Bax-like BH3 protein

(2009) L P Billen et al.   ONCOGENE

PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells

(2009) Q Sun et al.   ONCOGENE

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

(2009) A. C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death

(2008) Dipanjan Chowdhury et al.   Annual Review of Immunology

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

(2008) D. S. Levy et al.   BLOOD

The x c − cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine

(2008) Jun Guan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo

(2008) M. Vogler et al.   CANCER RESEARCH

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents

(2008) I. N. Fleming et al.   CLINICAL CANCER RESEARCH

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

Structural and Functional Basis for Therapeutic Modulation of p53 Signaling

(2008) E. A. Bassett et al.   CLINICAL CANCER RESEARCH

Tumor resistance to apoptosis

(2008) Simone Fulda   INTERNATIONAL JOURNAL OF CANCER

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

(2008) Niklas Finnberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK

(2008) Brian J Zarnegar et al.   NATURE IMMUNOLOGY

Is NF-κB a good target for cancer therapy? Hopes and pitfalls

(2008) Véronique Baud et al.   NATURE REVIEWS DRUG DISCOVERY

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY